- Abstract:
-
Objectives
Expand abstract
To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.
Methods
Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the first course and ≥16 weeks following further courses. Retreatment required evidence of clinical ... - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Files:
-
-
(pdf, 1.2MB)
-
- Publisher copy:
- 10.1371/journal.pone.0157961
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS One Journal website
- Volume:
- 11
- Issue:
- 6
- Pages:
- 320-330
- Chapter number:
- e0157961
- Publication date:
- 2016-06-23
- Acceptance date:
- 2016-06-05
- DOI:
- EISSN:
-
1932-6203
- ISSN:
-
1932-6203
- URN:
-
uri:b767952c-880b-49f3-8dc3-5c8caea843fa
- UUID:
-
uuid:b767952c-880b-49f3-8dc3-5c8caea843fa
- Local pid:
- pubs:656055
- Paper number:
- 6
- Copyright holder:
- Quattrocchi et al.
- Copyright date:
- 2016
- Notes:
- © 2016 Quattrocchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Journal article
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
GlaxoSmithKline Pharmaceuticals
More from this funder
Genmab
More from this funder
Bibliographic Details
Item Description
Terms of use
If you are the owner of this record, you can report an update to it here: Report update to this record